CytomX management will participate in several #investor conferences this month. Details here: bit.ly/4xyHVNe A live webcast of the presentation will also be available on the Events and Presentations page of our website.

We are pleased to share that the #FDA has granted Fast Track designation to Varseta-M, for the treatment of patients with R/R mCRC. More details in our latest press release: bit.ly/4ixKw5b #CRC #Oncology

Today, we shared Q2 2026 financial results, highlighting pipeline progress across key indications, including upcoming data for our Phase 1 clinical study for Varseta-M in #CRC by the end of 2026. Read the latest release or join our live webcast: bit.ly/4q40S7B

Today we welcome Alejandra Carvajal as our new CLO. Her deep track record in strategic biotech operations will be invaluable to further executing on our PROBODY pipeline. Read more: bit.ly/4fPTJmo #BiotechLeaders #OncologyLeaders #ColorectalCancer

Welcome, Charles Fuchs, M.D., M.P.H., to our Board of Directors. Dr. Fuchs' deep experience in GI cancers and cancer epidemiology will be an incredible asset during this critical period of growth. Read more here: bit.ly/4pPoeh6 #BiotechLeaders #OncologyLeaders

Join our CEO & Chairman, Sean McCarthy, as he presents today during the 44th Annual @jpmorgan Healthcare Conference at 9:00 am PST. Listen to the live webcast or catch the replay here: bit.ly/49mNBPe #JPMHC26

CytomX will be at the @Piper_Sandler 37th Annual Healthcare Conference today! Our CEO, Sean McCarthy, is participating in a fireside chat at 1:00 pm ET. Join the live webcast or access the replay later from our website: ir.cytomx.com/events-and-pre…

Our CEO, Sean McCarthy, DPhil, is participating in a fireside chat tomorrow, November 20, at the @Jefferies London Healthcare Conference. Join the live webcast at 1:00 pm GMT / 8:00 am EST or access the replay from our website: ir.cytomx.com/events-and-pre…

We shared Q3 2025 financial results, highlighting upcoming Q1 2026 Phase 1 CX-2051 data update in CRC, Phase 1b CX-2051/bevacizumab CRC combo study to start Q1 2026, and positive CX-801 biomarker data at #SITC25 support ongoing KEYTRUDA® combo in #melanoma bit.ly/3WHZWYE

Join us @sitcancer as we present initial translational data from the Phase 1 study of CX-801. These data support our ongoing combination study with KEYTRUDA® in advanced #melanoma from which we anticipate sharing data in 2026. bit.ly/3JH1cIm #SITC25

We’re expanding our leadership team with the appointment of Rachael Lester as SVP, Chief Business Officer. Her experience leading corporate strategy, business development and product portfolio planning, will be invaluable as we progress our pipeline. bit.ly/3WODAoa

Becoming a public co 10 yrs ago was a major step forward in support of our mission to transform the lives of people with cancer. Today, we reflect on the innovation & commitment that continue to drive us to develop safer, more effective therapies. Thx @Nasdaq for honoring this!

Today, we’ll be at the @HCWCO 27th Annual Global Investment Conference presenting at 11:30 AM ET and tomorrow we have a fireside chat at 1:05 PM ET at the @MorganStanley 23rd Annual Global Healthcare Conference. Join the webcast or catch the replay: bit.ly/3VaJBuJ

We’re happy to be here at the @Official_Cantor Global Healthcare Conference today in NYC! Looking forward to our fireside chat at 8:35 AM ET. Join our webcast here: bit.ly/4g21e9u #CantorHealthcare

Join us today as we share our Q2 2025 financial results and exciting pipeline progress, which included positive interim data for CX-2051 in advanced #colorectalcancer. A CX-2051 Phase 1 data update is anticipated in 1Q 2026. Learn more: bit.ly/4mysvCH